Chemours price target raised to $17 from $15 at Morgan Stanley

Morgan Stanley analyst Vincent Andrews raised the firm’s price target on Chemours (CC) to $17 from $15 and keeps an Equal Weight rating on the shares. While the firm reduced its EBITDA forecasts, it increased its price target to reflect higher peer multiples.